Myriad Genetics

"'I was leaving my mammogram and I said, 'Oh yeah, my dad's BRCA1 positive.' And the radiologist's whole face changed," @JackieTohn recalls. "I got really nervous, but I was playing it off.'" Tohn's doctor made sure she had the genetic testing done right then before leaving her appointment, and a few weeks later, in June 2025, she received her results." 👉Read more from @people: people.com/jackie-tohn-pr… 👉Learn more: myriad.com/learnmyrisk/?u… #myrisk #partners #genetictesting

"For @JackieTohn, the last few years have been a rollercoaster. The 'Nobody Wants This' star has been on a career high. But she's also been going through a challenging personal health journey behind the scenes. Now, she's sharing her story publicly in the hopes that others learn about their own genetic risk factors for breast cancer." 👉Read more from the @TODAYshow: today.com/health/breast-… 👉Learn more: myriad.com/learnmyrisk/?u… #genetictesting #partners #myrisk

Myriad Genetics joins forces with Nobody Wants This actress @JackieTohn to raise awareness about the importance of hereditary cancer testing with the MyRisk® Hereditary Cancer Test. 👉See more: investor.myriad.com/news-releases/… #partners #myrisk

We're heading to World Clinical Biomarkers & Companion Diagnostics Summit Japan and kicking things off with a pre-conference Engager focused on one of the most impactful frontiers in precision oncology: ultra-sensitive, tumor-informed MRD testing. 📍Hyatt Regency Tokyo | May 18 - 20, 2026 🧬Pre-Conference Engager | Monday, May 18, 4 PM JST Introducing Myriad's Ultra-Sensitive Tumor-Informed MRD Assay Join this deep-dive session to explore how tumor-informed MRD testing is being applied in real clinical and therapeutic development settings, and how MRD insights are shaping patient management, trial design, and drug development decisions today. Our Engager and plenary sessions will feature insights from: 🔹Dr. Bora Lim, Section Chief & Translational Research Director, MD Anderson 🔹Dr. Pavlos Msaouel, Associate Professor of Genitourinary Medical Oncology, MD Anderson 🔹Dale Muzzey, Chief Scientific Officer, Myriad Genetics 🔹Lou Welebob, Senior Vice President, Companion Diagnostics, Myriad Genetics Whether you're advancing biomarker-driven trials or planning next-generation CDx strategies, this session delivers practical perspectives you can apply across your programs. 👉 Register your interest to attend: cdx-japan.com #WorldCBDxJapan #MRD #precisiononcology #companiondiagnostics #biomarkers #liquidbiopsy #clinicaldevelopment

False-negative #cysticfibrosis results can undermine clinical confidence and delay meaningful follow-up. When other prenatal screens rely on only screening for limited variants, certain CFTR pathogenic variants may go unrecognized. The FirstGene® Multiple Prenatal Screen uses advanced AMPLIFY® technology and analytical modeling to deliver up to 99.9% detection of CFTR variants.* Explore how the AMPLIFY® difference can improve CF detection: myriad.com/prenatal-care/… #cfscreening #prenatalscreening #genomics #mfm #obgyn *Wang, J. S., Battey, C. J., Trettin, K., Patel, R., Srinivasan, A., Saikumar, J., Kushnoor, D., Habermeyer, B. F., Ganesh, S., Xu, N., et al. (2026). Simultaneous prenatal cfDNA screening of aneuploidy, recessive single-gene conditions, and fetomaternal blood compatibility. Clinical Chemistry. Advance online publication. academic.oup.com/clinchem/advan…

🎉 That's a wrap on #ACOG2026! We had an incredible time in D.C., unveiling the FirstGene® Multiple Prenatal Screen and connecting with so many of you to discuss the future of genetic insight-driven care. Through in-depth conversations and our Claw Machine Challenge, we shared how solutions like the FirstGene® screen are designed to reduce complexity and bring greater clarity to prenatal screening. #teamMyriad @acog

We're proud to contribute to the latest research advancing cancer care and to present new data on the Precise MRD™ Test at this year's #ASCO26 Annual Meeting: The Place to Behold the Future of Cancer Care. These abstracts highlight the role of the Precise MRD™ Test across multiple cancer types, underscoring Myriad's leadership in developing evidence that supports more precise and personalized molecular residual disease (MRD) testing. Attend one of the sessions below or visit Myriad at booth # 25081 to learn how our expanding portfolio of advanced genetic, tumor genomic, and molecular residual disease testing solutions helps empower clinicians with the clarity needed to improve patient outcomes and advance the future of precision oncology. Learn more or request a dedicated meeting: myriad.com/oncology/oncol… #oncology #myriadoncology #geneticinsights @ASCO

Today, we announced that Myriad management will participate in two upcoming healthcare conferences. 👉Read more: investor.myriad.com/news-releases/…

Yesterday, we announced financial results for our first quarter ended March 31, 2026, and reaffirmed our financial guidance for the full-year 2026. 👉Read more: investor.myriad.com/news-releases/…

Our team is onsite at #ACOG2026 this week engaging with clinicians and introducing the FirstGene® Multiple Prenatal Screen, including an interactive Claw Machine Challenge designed to demonstrate a simpler approach to prenatal screening. Stop by booth # 331 to connect with our team or learn more at myriad.com/WHconferences/. #genetictesting #teamMyriad #firstgene #prenatalscreening @acog

Today we announced that the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc., reveals that Americans feel mental health treatment isn't designed with them in mind. 👉 Read more: investor.myriad.com/news-releases/… #mentalhealth #newresearch

When it comes to cystic fibrosis screening, what you don't test for matters. Some standard mutation panels may miss more rare variants, leading to false-negative results and a false sense of reassurance. The Foresight Carrier Screen goes further with full-exon CFTR sequencing plus copy number analysis, capturing both common and rare variants. With earlier identification and clearer insight into carrier status, clinicians can better support informed reproductive planning before pregnancy.* See how the lab you partner with for CF screening can make a difference: myriad.com/genetic-tests/…. #carrierscreening #genetictesting #obgyn #genomics #mfm #cysticfibrosis #reproductivehealth *Beauchamp KA, Johansen Taber KA, Grauman PV, et al. “Sequencing as a first‑line methodology for cystic fibrosis carrier screening.” Genetics in Medicine. 2019;21(11):2569‑2576. | investor.myriad.com/news-releases/…

We're headed to the #ASCO26 Annual Meeting: The Place to Behold the Future of Cancer Care next month to share how our precision testing solutions support confident, guideline-driven decisions across the cancer care continuum! Join our Industry Expert Theater* featuring Dale Muzzey, PhD, for an introduction to the Precise MRD™ Test. This session will cover assay technical details and emerging clinical evidence across multiple solid tumors, including breast and colorectal cancers, and explore the role of highly sensitive molecular residual disease (MRD) detection across the care continuum. 👉Learn more or request a dedicated meeting: myriad.com/oncology/oncol… #oncology #myriadoncology #geneticinsights *Not an official event of the 2026 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. Not CME-accredited.

Today we announced we will hold our first quarter 2026 earnings conference call at 4:30 pm ET on Tuesday, May 5, 2026. 👉Read more: investor.myriad.com/news-releases/…

Don't miss our industry-hosted symposium in Washington, D.C. on Sunday, May 3: FirstGene® Multiple Prenatal Screen: Advancing Prenatal Screening Through Integrated Technology This session will explore how a single-draw prenatal screen can assess multiple genetic risks at once, using real-world cases to highlight test design, AMPLIFY® technology, and how integrated results may help address common clinical challenges. Register here: abstractsonline.com/pp8/#!/21317/s… Sunday, May 3 | 7 - 7:45 AM Room 206 #PrenatalScreening #GeneticTesting #FirstGene #WomensHealth This Industry Workshop is a promotional activity and is not approved for continuing education credit. The content of this Industry Workshop and opinions expressed by presenters are those of the sponsor or presenters and not of the American College of Obstetricians and Gynecologists.

We're proud to be sharing new scientific research at #ACOG2026. Our team will be presenting abstracts across prenatal screening, hereditary cancer risk assessment, and digital genomics workflows, including data on fetal fraction amplification, polygenic risk prediction, and expanded insights into endometrial cancer. Visit Booth # 311 to learn more and discuss the science with our team. #ClinicalResearch #Genomics #PrenatalCare #HereditaryCancer

Thrilled to share that we have been named to @Forbes' 2026 America's Best Employers for Company Culture list: forbes.com/lists/employer…. This recognition reflects the environment we strive to nurture together every day & is especially meaningful as it is based on anonymous employee feedback. Thank you to #teamMyriad, whose passion, expertise, and commitment to advancing health and well-being for all helps shape our culture - where everyone can thrive and do meaningful work. 💙 #companyculture #bestemployers

We're headed to #ACOG2026 in Washington, D.C., May 1 - 3. Visit Myriad Genetics at Booth # 331 to explore emerging science and integrated technologies supporting prenatal screening and hereditary cancer risk assessment. Our team will also be presenting new scientific abstracts across prenatal screening, hereditary cancer risk assessment, and digital genomics workflows. #ClinicalResearch #Genomics #PrenatalCare #HereditaryCancer

This week, we recognize Medical Laboratory Professionals Week and proudly celebrate the laboratory professionals who make our work possible. Behind every result is a team of highly skilled experts whose dedication to quality, accuracy, and precision plays a critical role in delivering insights that help inform important healthcare decisions. Thank you to our lab professionals for the meaningful impact you make at Myriad every day! 💙 👉myriad.com/genetic-tests/ #MedicalLaboratoryProfessionalsWeek #teamMyriad #genetictesting

🧬Myriad Genetics Scientific Presentations at AACR 2026 In addition to our spotlight sessions, Myriad Genetics and collaborators will present six abstracts at #AACR 2026, including two podium presentations and multiple posters highlighting new data across #MRD, liquid biopsy, genomic classifiers, and cancer risk. Presentations feature work from Myriad scientists and leading academic collaborators across breast and prostate cancer research: investor.myriad.com/news-releases/… 📍@AACR Annual Meeting 2026 🗓 April 17 - 22 | San Diego We look forward to engaging with the research community throughout the meeting. #AACR2026 #precisiononcology #liquidbiopsy #cancergenomics